Liposomes Market To Expand Based On Agile Supply Chains At A CAGR Of 7%

Liposomes Market is expected to grow on an impertinent note in the next 10 years. It could witness a CAGR of 7% by 2030. Data processing through Big Data is on the anvil. Clinical software solutions are there to help out, taking the help of Big Data. Thus, data accumulation as well as analytics would be there in a precise manner. This would be the probable facts with healthcare vertical in future.

Liposomes are a novel system widely used in the field of drug delivery, gene delivery, medical imaging, and model cell membrane biology. Stealth liposome technology, DepoFoam technology, and non-PEGylated liposomal technology are gaining significant adoption in the development of liposome-based products.

Growing research & development activities for the delivery of anti-fungal, anti-cancer, anti-inflammatory drugs, and therapeutic genes are boosting the demand for liposome formulations.

Liposomes have the ability to overcome the limitations of conventional therapy and provide benefits in various therapeutic applications, ranging from cancer to pain management. Encapsulation of drugs in liposomes improves the therapeutic indices of various agents.

Get Going With Sample Of Liposomes Market Report! https://www.persistencemarketresearch.com/samples/16546

According to PMR, the global liposomes market was valued at US$ 6.5 Bn in 2019, and is expected to expand at a CAGR of around 7% during the forecast period (2020-2030).

Company Profiles:

Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd
Johnson & Johnson
Dr. Reddy's Laboratories Ltd.
Sun Pharma Industries Ltd
Baxter AG
Sanofi SA
Bristol Myers Squibb
Mylan NV
GlaxoSmithKline Plc.
Creative Biolabs
Precision NanoSystems Inc.
SkyePharma Inc.
Luye Pharma Group
Encapsula NanoSciences LLC
Nanovex Biotechnologies SL
Gilead Sciences, Inc.
Avanti Polar Lipids, Inc.
Fujifilm Holdings Corporation

How about re-inventing the methodical wheel in the Liposomes Market? Switch over to the "Methodology" tab! https://www.persistencemarketresearch.com/methodology/16546

Key Takeaways from Liposomes Market Study

Formulated liposomes occupied nearly 68% of the market value share in the liposomes market in 2019, owing to increasing adoption of liposome-based drug formulations. Doxorubicin and paclitaxel formulated liposomes contributed more than three-fifth of market value share in the global liposomes market.

Drug delivery applications accounted the highest market value share in the global liposomes market, on the back of rising demand for nanotechnology drug delivery. The cancer drug delivery application segment is expected to progress at the highest growth rate, due to increasing R&D activities to develop drugs for cancer.

Distributional sales hold a major share in the global liposomes market, owing to the growing demand for formulated liposomal drugs.

North America holds a prominent revenue share in the global liposomes market, as a result of rising prevalence of cancer and fungal diseases in the region. However, the liposomes market in East Asia is projected to flourish at the highest growth rate, owing to increasing pharmaceutical expenditure in the region.

The race for liposomal vaccine development to combat the ongoing COVID-19 pandemic is a catalyst for the growth of the global liposomes market.

"Rising demand for liposomal formulations and vaccines, and increasing research activities in the field of biomolecules and gene delivery, are expected to favor the growth of the liposomes market," says a PMR analyst.

Keeping A Tab On Key Players In The Liposomes Market? Go To "Purchase Now" To Decipher The Competitive Analysis In Our Liposomes Market Report! https://www.persistencemarketresearch.com/checkout/16546

Product Portfolio Expansion and Regulatory Approval - Key Strategies of Leading Liposome Manufacturers

Manufacturers in the liposomes market are focusing on product portfolio expansion and new product launches. For instance, in September 2017, Novartis received EU approval for the Rydapt® (midostaurin) drug for FLT3-mutated acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis. Manufacturers are focusing on acquiring regulatory approval in different countries for the expansion of product sales.

For instance, in October 2017, GlaxoSmithKline Plc. declared that the US Food and Drug Administration approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles in adults aged 50 years and above.

More Valuable Insights on Liposomes Market

Persistence Market Research offers a unique perspective and actionable insights on the liposomes market in its latest study, presenting historical demand assessment of 2015-2019 and projections for 2020-2030, on the basis of product (simple liposomes, formulated liposomes {doxorubicin liposomes, amphotericin B liposomes, paclitaxel liposomes, cytarabine liposomes, irinotecan liposomes, cisplatin liposomes, and others}, and vaccines), application (drug delivery {cancer, fungal infection, viral & parasite infection, and others}, gene delivery/transfection, contrast agents for medical imaging, and model cell membranes), distribution channel (retail sales {academic & research laboratories, biopharmaceutical companies, clinical research organizations, and others} and distributional sales {hospital pharmacies, retail pharmacies, mail order pharmacies, and drug stores}), across seven major regions.

Access Related Reports-

Diabetic Nephropathy Market: https://www.persistencemarketresearch.com/market-research/diabetic-nephropathy-market.asp

Malignant Mesothelioma Market: https://www.persistencemarketresearch.com/market-research/malignant-mesothelioma-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.